Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2026-08-18

EMA Authorised: Stelara (ustekinumab) — Janssen-Cilag International NV

View source ↗

Summary

EU authorises Stelara (ustekinumab) for multiple indications including psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Stelara (ustekinumab)

Snippet

Status: Authorised. Therapeutic area: Psoriasis;Arthritis, Psoriatic;Crohn Disease;Colitis, Ulcerative. MAH: Janssen-Cilag International NV. Decision date: 23/07/2026